3706.
e4 PART XV The Prostate
Sartor O, Myers C: The influence of aminoglutethimide and corticosteroids
on the therapeutic benefits of flutamide withdrawal, Proc Am Soc Clin
Oncol 14:245, 1995.
Sartor O, Reid RH, Hoskin PJ, et al: Samarium-153–lexidronam complex for
treatment of painful bone metastases in hormone-refractory prostate cancer,
Urology 63:940–945, 2004.
Scagliotti GV, Novello S, von Pawel J: The emerging role of MET/HGF inhibitors
in oncology, Cancer Treat Rev 39:793–801, 2013.
Scher HI, Eisenberger M, D’Amico AV, et al: Eligibility and outcomes reporting
for clinical trials for patients in the state of a rising PSA: recommendations
from the Prostate-Specific Antigen Working Group, J Clin Oncol 22:537–556,
2004.
Scher HI, Fizazi K, Saad F, et al: Impact of on-study corticosteroid use on
efficacy and safety in the phase III AFFIRM study of enzalutamide, an
androgen receptor inhibitor, J Clin Oncol 31(Suppl 6):2013. abstract 6.
Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in
prostate cancer after chemotherapy, N Engl J Med 367:1187–1197, 2012.
Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials
for patients with progressive prostate cancer and castrate levels of testos-
terone: recommendations of the Prostate Cancer Clinical Trials Working
Group, J Clin Oncol 26:1148–1159, 2008.
Scher HI, Kelly KW: Flutamide withdrawal syndrome: its impact on clinical
trials in hormone refractory prostate cancer, J Clin Oncol 11:1566–1572,
1993.
Scher HI, Lu D, Schreiber NA, et al: Association of AR-V7 on circulating
tumor cells as a treatment-specific biomarker with outcomes and survival
in castration-resistant prostate cancer, JAMA Oncol 2:1441–1449, 2016.
Schwarz EM, Ritchlin CT: Clinical development of anti-RANKL therapy, Arthritis
Res Ther 9(Suppl):S7, 2007.
Seckin B, Anthony CT, Murphy B, et al: Can prostate-specific antigen be used
as a valid end point to determine the efficacy of chemotherapy for advanced
prostate cancer?, World J Urol 14:S26–S29, 1996.
Semenza GL: Targeting HIF-1 for cancer therapy, Nat Rev Cancer 3:721–732,
2003.
Slovin SF, Higano CS, Hamid O, et al: Ipilimumab alone or in combination
with radiotherapy in metastatic castration-resistant prostate cancer: results
from an open-label, multicenter phase I/II study, Ann Oncol 24:1813–1821,
2013.
Smaletz O, Scher H, Small EJ, et al: Nomogram for survival of patients with
progressive metastatic prostate cancer after castration, J Clin Oncol
20:3972–3982, 2002.
Small EJ, Halabi S, Dawson NA, et al: Antiandrogen withdrawal alone or in
combination with ketoconazole in androgen independent prostate cancer:
a phase III trial (CALGB 9583), J Clin Oncol 22:1025–1033, 2004.
Small EJ, Schellhammer PF, Higano CS, et al: Placebo-controlled phase III
trial of immunologic therapy with sipuleucel-T (APC8015) in patients
with metastatic, asymptomatic hormone refractory prostate cancer, J Clin
Oncol 24:3089–3094, 2006.
Small EJ, Tchekmedyian NS, Rini BI, et al: A pilot trial of CTLA-4 blockade
with human anti–CTLA-4 in patients with hormone-refractory prostate
cancer, Clin Cancer Res 13:1810–1815, 2007.
Smith DC, Smith MR, Sweeney C, et al: Cabozantinib in patients with advanced
prostate cancer: results of a phase II randomized discontinuation trial, J
Clin Oncol 31:412–419, 2013.
Smith M, De Bono J, Sternberg C, et al: Phase III study of cabozantinib in
previously treated metastatic castration-resistant prostate cancer: COMET-1,
J Clin Oncol 34(25):3005–3013, 2016.
Smith MR, Eastham J, Gleason D, et al: Randomized controlled trial of
zoledronic acid to prevent bone loss in men receiving androgen deprivation
therapy for nonmetastatic prostate cancer, J Urol 169:2008–2012, 2003.
Smith MR, Kabbinavar F, Saad F, et al: Natural history of rising serum PSA
in men with castrate nonmetastatic prostate cancer, J Clin Oncol
23:2918–2925, 2005.
Smith MR, McGovern FJ, Zietman AL, et al: Pamidronate to prevent bone
loss during androgen-deprivation therapy for prostate cancer, N Engl J
Med 345:948–955, 2001.
Smith MR, Saad F, Chowdhury S, et al: Apalutamide treatment and metastasis-
free survival in prostate cancer, N Engl J Med 378(15):1408–1418, 2018.
Smith PH, Suciu S, Robinson MRG, et al: A comparison of the effect of
diethylstilbestrol with low dose estramustine phosphate in the treatment
of advanced prostatic cancer: final analysis of a phase III trial of the European
Organization for Research on Treatment of Cancer, J Urol 136:619–623,
1986.
Sorensen PS, Borgensen SE, Rohde K: Metastatic epidural spinal cord compres-
sion: results of treatment and survival, Cancer 65:1502–1510, 1990.
Sowery RD, Hadaschik BA, So AI, et al: Clusterin knockdown using the
antisense oligonucleotide OGX-011 resensitizes docetaxel-refractory prostate
cancer PC-3 cells to chemotherapy, BJU Int 102:389–397, 2008.
Steiner MS: Role of peptide growth factors in the prostate, Urology 42:99–110,
1993.
Sternberg C, Armstrong A, Pili R, et al: Randomized, double-blind, placebo-
controlled Phase III study of tasquinimod in men with metastatic castration-
resistant prostate cancer, J Clin Oncol 34(22):2636–2643, 2016.
Stigliano A, Gandini O, Cerquetti L, et al: Increased metastatic lymph node
64 and CYP17 expression are associated with high stage prostate cancer,
J Endocrinol 194:55–61, 2007.
Storlie J, Buckner J, Wiseman G, et al: Prostate specific antigen levels and
clinical response to low dose dexamethasone for hormone-refractory
metastatic prostate carcinoma, Cancer 76:96–100, 1995.
Tannock I, DeWit R, Berry W, et al: Docetaxel plus prednisone or mitoxantrone
plus prednisone for advanced prostate cancer, N Engl J Med 351:1502–1512,
2004.
Tannock I, Fizazi K, Ivanov S, et al: Aflibercept versus placebo in combination
with docetaxel and prednisone for treatment of men with metastatic
castration-resistant prostate cancer (VENICE): a phase III, double-blind
randomized trial, Lancet Oncol 14:760–768, 2013.
Tannock I, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone
plus prednisone or prednisone alone for symptomatic hormone-resistant
prostate cancer: a Canadian randomized trial with palliative endpoints, J
Clin Oncol 14:1753–1755, 1996.
Taylor BS, Schultz N, Hieronymus H, et al: Integrative genomic profiling of
human prostate cancer, Cancer Cell 18:11–22, 2010.
Taylor CD, Elson P, Trump DL: Importance of continued testicular suppression
in hormone-refractory prostate cancer, J Clin Oncol 11:2167–2172, 1993.
Tran C, Ouk S, Clegg NJ, et al: Development of a second-generation antian-
drogen for treatment of advanced prostate cancer, Science 324:787–790,
2009.
Trusolino L, Bertotti A, Comoglio PM: MET signaling: principles and functions
in development, organ regeneration and cancer, Nat Rev Mol Cell Biol
11:834–848, 2010.
Van den Wyngaert T, Huizing MT, Fossion E, et al: Bisphosphonates in
oncology: rising stars or fallen heroes, Oncologist 14:181–191, 2009.
Verras M, Lee J, Xue H, et al: The androgen receptor negatively regulates the
expression of c-Met: implications for a novel mechanism of prostate cancer
progression, Cancer Res 67:967–975, 2007.
Watson PA, Chen YF, Balbas MD, et al: Constitutively active androgen receptor
splice variants expressed in castration-resistant prostate cancer require
full-length androgen receptor, Proc Natl Acad Sci USA 107:16759–16765,
2010.
Webster WS, Small EJ, Rini BI, et al: Prostate cancer immunology: biology,
therapeutics, and challenges, J Clin Oncol 23:8262–8269, 2005.
Wozney JL, Antonarakis ES: Growth factor and signaling pathways and their
relevance to prostate cancer therapeutics, Cancer Metastasis Rev 33(2–3):581–
594, 2014.
Yap TA, Yan L, Patnaik A, et al: First-in-man clinical trial of the oral pan-AKT
inhibitor MK-2206 in patients with advanced solid tumors, J Clin Oncol
29:4688–4695, 2011.
Zhu ML, Horbinski CM, Garzotto M, et al: Tubulin-targeting chemotherapy
impairs androgen receptor activity in prostate cancer, Cancer Res
70:7992–8002, 2010.
Zoubeidi A, Chi K, Gleave M: Targeting the cytoprotective chaperone, clusterin,
for treatment of advanced cancer, Clin Cancer Res 16:1088–1093, 2010.